ReviewMedical oncology (Northwood, London, England)2024
Targeted gene therapy for cancer: the impact of microRNA multipotentiality.
Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma.Gene therapy · 2026Article
- Hypoxia Signaling and Non-Coding RNAs: Regulatory Networks and Therapeutic Implications in Breast Cancer.Current issues in molecular biology · 2026Review
- Targeting TGF-β signaling in glioblastoma: therapeutic implications and novel drug development strategies.Brain tumor pathology · 2025Review
- Exosomal MicroRNA: Diagnostic Potential and Role in Breast Cancer Dissemination.Molecules (Basel, Switzerland) · 2025Review
- The emerging role of miR-362 in cancer: expression and function across different cancer types.Medical oncology (Northwood, London, England) · 2025Review
- Bioinformatics identification of key microRNA-correlated genes associated with hepatocellular carcinoma heterogeneity and prognosis.BMC gastroenterology · 2025Article
- Small interfering RNA: From designing to therapeutic in cancer.Journal, genetic engineering & biotechnology · 2025Review
- Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Dual-regulatory miRNAs: master regulators and therapeutic targets in bone-metastatic breast cancer.Frontiers in molecular biosciences · 2025Review
- Letter to the editor on "Targeted gene therapy for cancer: the impact of microRNA multipotentiality".Medical oncology (Northwood, London, England) · 2024Article
- Unveiling hotspots of emerging research in the miRNA-related mechanism underlying cancer through comprehensive bibliometric analysis with implications for precision medicine and non-invasive diagnostics.Frontiers in oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a life-threatening disease and its management is difficult due to its complex nature. Cancer is characterized by genomic instability and tumor-associated inflammation of the supporting stoma. With the advances in omics science, a treatment strategy for cancer has emerged, which is based on targeting cancer-driving molecules, known as targeted therapy. Gene therapy, a form of targeted therapy, is the introduction of nucleic acids into living cells to replace a defective gene, promote or repress gene expression to treat a disease. MicroRNAs (miRNAs) are non-coding RNAs (ncRNAs) that regulate gene expression and thus are involved in physiological processes like cell proliferation, differentiation, and cell death. miRNAs control the actions of many genes. They are deregulated in cancer and their abnormal expression influences genetic and epigenetic alterations inducing carcinogenesis. In this review, we will explain the role of miRNAs in normal and abnormal gene expression and their usefulness in monitoring cancer patients. Besides, we will discuss miRNA-based therapy as a method of gene therapy and its impact on the success of cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.